Abstract:Introduction: Liver transplantation (LT) is a life-saving procedure that resolves complications of cirrhosis. However, the metabolic risk factors for nonalcoholic fatty liver disease (NAFLD) persist and potentially worsen in the post-transplant setting, thereby increasing the risk of liver fibrosis. Liver biopsy is the gold standard to diagnose NAFLD and liver fibrosis, but this procedure is invasive and less than ideal for longitudinal monitoring after LT. We aimed to investigate the association of serum steatosis and fibrosis biomarkers with mortality and graft loss in LT recipients. Methods: We included consecutive adults who received a liver transplant at the MUHC in 2014-2021 and were followed up annually. The outcomes measured were death and graft loss, graft loss being defined as graft failure leading to death or re-transplantation. We assessed the prognostic value of the biomarkers ALT, AST, GGT, AST-to-Platelet Ratio Index (APRI), fibrosis-4 index (FIB-4), and hepatic steatosis index (HSI). Hepatic steatosis was defined as HSI >36, and liver fibrosis was characterized as FIB-4 > 3.64 or APRI > 1. Survival analysis and Generalized Estimating Equation (GEE) models were used to assess the association between the biomarkers and the outcomes. Results: Two hundred nineteen patients were followed for 30 months on average. Graft loss and mortality occurred in 12 patients (9%) and 38 (29.5%) resulting in incidence rates of 29.5 (95% CI 20.9-40.6) and 9.6 (95% CI 5-16.8) per 100 person-years, respectively. Patients who died during the follow-up were older, had an older donor, and had a history of diabetes. On multivariable analysis using the GEE model (see Table 1), higher ALT and higher AST were associated with mortality after adjustment for sex, BMI, age, albumin, and platelets. In the time-to-event analysis, the Kaplan Meier curves showed that APRI >1 could be a potential predictor of mortality (P = 0.0729 see Figure 1). Neither FIB-4 (log-rank, P = 0.199) nor HSI (log-rank, P = 0.919) were associated with mortality. None of the biomarkers or liver transaminases were associated with graft loss. Conclusion: Liver transaminases and the serum fibrosis biomarker APRI are associated with mortality in LT recipients. The hepatic steatosis biomarker HSI does not seem to be valuable in predicting outcomes in this population. None among liver transaminases, steatosis or fibrosis biomarkers predicted graft loss. Table 1. - GEE of liver transaminases on death in LT patients Characteristics Univariate Multi-Variate * Odds Ratio 95% CI P-value Odds Ratio 95% CI P-value ALT Moderate/Severe 0.9999 0.9999–1.0000 0.0931 1.0001 1.0000–1.0002 0.0040 AST Moderate/Severe 1.0000 0.9999–1.0000 0.3934 1.0001 1.0000–1.0001 0.0037 ALP Moderate/Severe 0.9999 0.9996–1.0001 0.2807 1.0000 0.9998–1.0001 0.6113 GGT Moderate/Severe 0.9998 0.9996–1.0000 0.0236 0.9998 0.9997–1.0000 0.0596 Smoking status No 1.00 1.00 Yes 0.921 0.71–1.20 0.5444 0.934 0.74–1.18 0.5649 *multivariate models are adjusted for age, sex, albumin, BMI and platelets. Figure 1.: Kaplan-Meier survival curve in LT patients according to the APRI biomarker.

Increased Pretransplant Inflammatory Biomarkers Predict Death With Function After Kidney Transplantation

A Statistical Prediction Model for Survival after Kidney Transplantation from Deceased Donors

Pretransplant Renal Function Evaluated by Serum Cystatin C Was Associated with Mortality after Liver Transplantation: a Single-Center Experience

[Influence of Pre-Transplant Serum Level of Soluble CD30 on the Long-Term Survival Rates of Kidney Transplant Recipients and Grafts].

Evaluation of biomarkers of cell cycle arrest and inflammation in prediction of dialysis or recovery after kidney transplantation

Serum Fibrosis and Steatosis Biomarkers for the Prediction of Mortality in Liver Transplant Recipients

Early inflammatory markers as prognostic indicators following allogeneic stem cell transplantation

Pre-Operative Kidney Biomarkers and Risks for Death, Cardiovascular and Chronic Kidney Disease Events: The TRIBE-AKI Study

Circulating Cell Death Biomarkers May Predict Survival in Human Lung Transplantation

Preoperative examination of inflammatory biomarkers in relation to the prognosis of postoperative complications after heart transplantation

Dissecting Inflammation in ESRD: Do Cytokines and C-Reactive Protein Have a Complementary Prognostic Value for Mortality in Dialysis Patients?

Associations between inflammatory and angiogenic proteomic biomarkers, and cardiovascular events and mortality in relation to kidney function

The Predictive Value of Urinary Kidney Injury Molecular-1 for Long-Term Graft Function in Kidney Transplant Patients: a Prospective Study

Preoperative inflammatory biomarkers reveal renal involvement in postsurgical mortality in hip fracture patients: an exploratory study

Biomarkers of Cardiovascular Disease and Mortality Risk in Patients with Advanced CKD

Inflammatory Biomarkers to Predict Adverse Outcomes in Postoperative Patients with Acute Type A Aortic Dissection.

Plasma Macrophage Migration Inhibitory Factor Predicts Graft Function Following Kidney Transplantation: A Prospective Cohort Study

Invasive Fungal Diseases in Kidney Transplant Recipients: Risk Factors for Mortality

Pretransplant endotrophin predicts delayed graft function after kidney transplantation

Association between systemic inflammatory indicators with the survival of chronic kidney disease: a prospective study based on NHANES

An analysis of the relationship between donor and recipient biomarkers and kidney graft function, dysfunction, and rejection